NC-HEM-14-6: Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 (Anti-CD40L dAb) in Adult Subjects with Primary Immune Thrombocytopenia (ITP)
DescriptionThe purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.
PhasePhase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.
Inclusion and Exclusion Criteria
- ≥18 years old, diagnosed with persistent or chronic ITP
- Secondary immune thrombocytopenia
- Drug induced thrombocytopenia
Please contact Gangothri Namasivayam to learn more about where you can participate in this trial. Please use the contact form on the right side.